Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.

Vincent Ka Chun YanYu YangEric Yuk Fai WanFrancisco Tsz Tsun LaiCeline Sze Ling ChuiXue LiCarlos King Ho WongIvan Fan Ngai HungChak Sing LauIan Chi Kei WongEsther Wai Yin Chan

Published in: Drug safety (2024)

Tixagevimab-cilgavimab was effective in reducing COVID-19 infection among immunocompromised patients during the Omicron wave. Findings were consistent among individuals who previously received three or more doses of COVID-19 vaccine, or had no previous history of COVID-19 infection.

Keyphrases

end stage renal disease
coronavirus disease
ejection fraction
sars cov
newly diagnosed
peritoneal dialysis
prognostic factors
study protocol
respiratory syndrome coronavirus